NorthWest Biotherapeutics Inc (NWBO)

[Nemesis18]

The NICE’s Health Economist will reject DCVAX-L as a free at source NHS prescriptive treatment outright.
With a stated 87% failure rate to get anywhere near a meaningful result, to offset the cost to the NHS budget and wider economy, the NICE will refuse.
They are not there to help a biotech company stave off bankruptcy. Nor are any reserve cancer treatment funds there to help enrich purely speculative investors.
As the NICE are full off accountants, it is in their remit to forensically go through the Company’s books since inception, and it’s recent balance sheets.
It’s financial health now will also determine whether it will be a fiscally responsible supply partner moving forward.